References
1. Pimpin L, Cortez-Pinto H, Negro F, et al. Burden of liver disease in Europe: Epidemiology and analysis of risk factors to identify prevention policies. J Hepatol. 2018 Sep;69(3):718–35.
2. Bellentani S, Scaglioni F, Marino M, et al. Epidemiology of non-alcoholic fatty liver disease. Digestive Diseases. 2010. p. 155–61.
3. Caballería L, Pera G, Arteaga I, et al. High Prevalence of Liver Fibrosis Among European Adults With Unknown Liver Disease: A Population-Based Study. Clin Gastroenterol Hepatol. 2018 Jul;16(7):1138–1145.e5.
4. Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology. 2012;55(6):2005–23.
5. Bayard M, Holt J, Boroughs E. Nonalcoholic fatty liver disease. Am Fam Physician. 2006 Apr 18;73(11):1961–9.
6. Higuera-de la Tijera F, Servín-Caamaño AI. Pathophysiological mechanisms involved in non-alcoholic steatohepatitis and novel potential therapeutic targets. World J Hepatol. 2015;7(10):1297–301.
7. Ampuero J, Aller R, Gallego-Durán R, Banales JM, et al. The effects of metabolic status on non-alcoholic fatty liver disease-related outcomes, beyond the presence of obesity. Aliment Pharmacol Ther. 2018 Oct 23;
8. McPherson S, Hardy T, Henderson E, et al. Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management. J Hepatol. 2015 May;62(5):1148–55.
9. Ekstedt M, Hagström H, Nasr P, et al. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology. 2015 May;61(5):1547–54.
10. Sanchez-Torrijos Y, Ampuero J, Romero-Gómez M. Cardiovascular assessment in liver transplant for non-alcoholic steatohepatitis patients: What we do, what we should do. World J Hepatol. 2017 May 28;9(15):697.
11. Arora A, Sharma P. Non-invasive Diagnosis of Fibrosis in Non-alcoholic Fatty Liver Disease. J Clin Exp Hepatol. 2012 Jun;2(2):145–55.
12. Bhala N, Angulo P, van der Poorten D, et al. The natural history of nonalcoholic fatty liver disease with advanced fibrosis or cirrhosis: An international collaborative study. Hepatology. 2011 Oct;54(4):1208–16.
13. Lazo M, Hernaez R, Bonekamp S, et al. Non-alcoholic fatty liver disease and mortality among US adults: prospective cohort study. BMJ. 2011 Nov 18;343(nov18 2):d6891–d6891.
14. Almpanis Z, Demonakou M, Tiniakos D. Evaluation of liver fibrosis: ?Something old, something new?? Ann Gastroenterol. 2016;29(4):445–53.
15. Samperio-González MA, Selvi-Blasco M, Manzano-Montero M, et al. Prevalencia de la esteatosis hepática no alcohólica en población con hipertransaminasemia y grado de adecuación del diagnóstico registrado en atención primaria. Aten Primaria. 2016;48(5):281–7.
16. Gallego-Durán R, Ampuero J, Funuyet J, et al. Esteatohepatitis alcohólica y no alcohólica: ¿quiénes son los pacientes y qué podemos hacer por ellos? Gastroenterol Hepatol. 2013 Nov;36(9):587–96.
17. Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L, et al. Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis. Gastroenterology. 2015 Aug;149(2):367–378.e5.
18. Ampuero J, Sánchez-Torrijos Y, Aguilera V, et al. Nuevas perspectivas terapéuticas en la esteatohepatitis no alcohólica. Gastroenterol Hepatol. 2017 Sep 2;40.
19. Byrne CD, Targher G. EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. Diabetologia. European Association for the Study of the Liver; 2016;59(6):1141–4.
20. Reccia I, Kumar J, Akladios C, et al. Non-alcoholic fatty liver disease: A sign of systemic disease. Metabolism. 2017 Jul;72:94–108.